Giapreza Approval History
FDA Approved: Yes (First approved December 21, 2017)
Brand name: Giapreza
Generic name: angiotensin II
Dosage form: Injection
Previous Name: LJPC-501
Company: La Jolla Pharmaceutical Company
Treatment for: Hypotension, Shock
Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.
Development History and FDA Approval Process for Giapreza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.